REG - Imaging Biometrics - Fractional Tumor Burden Mapping Enhances GBM Trial

Imaging BiometricsAnnouncement

13/11/2025 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251113:nRSM4541Ha&default-theme=true

RNS Number : 4541H  Imaging Biometrics Limited  13 November 2025

Imaging Biometrics Limited

("IB" or the "Company")

 

Imaging Biometrics' Fractional Tumor Burden Mapping Enhances GBM Trial

 

A glioblastoma (GBM) clinical trial led by Dr. Danielle Bazer, DO,
neuro-oncologist and Lead for Neuro-Oncology at MD Anderson Cancer Center at
Cooper University, is leveraging IB's Functional Tumor Burden (FTB) mapping to
assess early treatment response and support key study endpoints. Funding for
the FTB mapping component was made possible in part by the Musella Foundation
for Brain Tumor Research & Information, Inc., whose support continues to
accelerate innovation in brain tumor research.

 

This phase 2 feasibility study explores a novel treatment paradigm for
patients with newly diagnosed high grade gliomas: administering temozolomide
chemotherapy prior to radiation therapy. This innovative approach aims to
determine whether early objective response rates-measured before radiation-can
serve as reliable surrogates for drug activity. If validated, this paradigm
could revolutionize early-phase clinical trial design in neuro-oncology,
enabling more efficient drug screening and personalized treatment strategies.

 

IB's FTB maps will provide voxel-level classification of tumor tissue based on
perfusion characteristics, distinguishing active tumor from necrosis and
treatment-related changes - a critical distinction that conventional imaging
often fails to make. By comparing baseline and post-treatment FTB maps, deeper
insights will be gained into tumor response trajectories and the biological
impact of early chemotherapy-particularly in MGMT methylated tumors, which are
known to respond more favorably to temozolomide.

 

"FTB mapping gives us a dynamic view of tumor behavior, which will help
provide confirmation of response to drug therapy" said Dr. Bazer.

 

"We're proud to support this trial with our imaging platform and grateful for
the financial support from the Musella Foundation," said Michael Schmainda,
CEO of Imaging Biometrics. "FTB mapping is designed to bring clarity to brain
tumor imaging, and we're excited to see it making a difference."

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 Imaging Biometrics Ltd

 Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 AlbR Capital Limited (Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of Imaging
Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on X, @ImgBiometrics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRGPGWPGUPAGGW



            Copyright 2019 Regulatory News Service, all rights reserved